Eric Lefkovsky’ Tempus Receives New Funding

Tempus Receives New Funding

Eric Lefkovsky has just ended another round of funding for his cancer research technology company, Tempus, which allows cancer patients to make more meaningful decisions about the treatments they seek. In this latest round of funding, Eric Lefkovsky was able to raise a total of $210M. The investors who have provided funding to the Eric Lefkovsky startup are Kinship Trust Company along with T. Rowe Price, Revolution Growth, and New Enterprise Associates. Presently Eric Lefkovsky is developing a gigantic data center which contains clinical and microscopic data. There is no database like this in existence. The database offers physicians a platform to find molecular data that enable them to make real-time decisions for patients. Tempus does not make medical decisions for patients but provides authorized physicians access to its database of low-cost data. Tempus is unique in that it bridges the gap between software engineers and scientist to produce a collaborative effort between the two. There are two kinds of scientist that use the database, which is computational and biological.

Vital Statistics

Records show that the United States has close to 17 million cancer patients at present. The number of documents on the molecular data for these patients covers only one-tenth of the number of patients. The treatment for the mystery of cancer depends upon having collected the most significant amount of molecular data possible to make it useful to scientist and accessible to those who are actively working to cure the mystery of cancer.

Real-Time Decision-Making Cancer Care

Tempus opens its interactive database of molecular data to deliver personalized cancer care for those who have cancer. Tempus provides a platform to make personalized prescriptive attention for patients thru authorized physician recommendations. By providing data for successful cancer treatment care, Tempus paves the way for real-time retrieval of solutions thru physicians real-time decision for their cancer patients.